secwatch.observer — SEC 8-K summary
======================================

Issuer:     89bio, Inc. (—)
CIK:        0001785173
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001193125-24-193906
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

89bio Q2 net loss $48M; appoints ex-CymaBay CSO Charles McWherter to board; Phase 3 MASH trials enrolling
--------------------------------------------------------------------------------

- Net loss $48.0M for Q2 2024 vs $38.4M YoY; R&D expenses rose to $44.9M.
- Cash, equivalents and marketable securities $531.4M as of June 30, 2024.
- Phase 3 ENLIGHTEN-Fibrosis (F2-F3 MASH) and ENLIGHTEN-Cirrhosis (F4) enrolling patients.
- Phase 3 ENTRUST (SHTG) topline data expected in 2025; enrollment ongoing.
- Charles McWherter, Ph.D., former CSO/President R&D of CymaBay (acquired by Gilead), appointed to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785173/000119312524193906/0001193125-24-193906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785173/000119312524193906/d879198d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-193906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer